A European Standard Clinical Practice Guidance has been published in the European Journal of Endocrinology on the diagnosis and treatment of adrenal and extra-adrenal paragangliomas in children and adolescents.
US researchers have created age- and sex-adjusted growth charts for use in children with classic congenital adrenal hyperplasia, reflecting the distinct patterns of height and weight among patients versus the general population.
The European Society for Paediatric Endocrinology (ESPE) has released a position statement to encourage further research into endocrine immune-related adverse events associated with the use of immune checkpoint inhibitors in children with cancer.
Children and young adults with congenital adrenal hyperplasia may be at long-term risk of low bone mineral density, with the greatest risk found in boys and young men, Italian researchers have found.
We are excited to welcome you to the Insights into MAnaging Growth for Endocrine nurses (IMAGE) June 2025 Meeting, organised by Springer Healthcare IME. This event will take place on 5–6 June 2025 in the vibrant city of Lisbon in Portugal.
Phase 3 trial findings support the use of an oral corticotropin-releasing factor type 1 receptor antagonist for the treatment of classic congenital adrenal hyperplasia in children with 21-hydroxylase deficiency.
Find out more about this group of rare autosomal recessive conditions affecting the adrenal cortex called Congenital adrenal hyperplasia (CAH).
Children and adolescents with congenital adrenal hyperplasia appear to have impaired psychosocial quality of life, particularly in the school domain, while physical QoL is preserved, suggest findings of a systematic review and meta-analysis.
Adrenal crisis occurs in a “substantial proportion” of individuals with paediatric- onset adrenal insufficiency, say the authors of a prospective cohort study based in Japan.
Research has demonstrated a dose–response relationship between the number of supernumerary X chromosomes in young people with high-grade aneuploidies and the level of endocrine system impairment experienced.
